Dual Specificity Protein Kinase TTK Market Increasing prevalence of cancer is expected to drive the market growth | Bayer AG, Pfizer Inc., Boston Pharmaceuticals

Overview:

Protein phosphorylation is an important mechanisms which is done by cells to regulate enzymatic activity, localization, functions and interactions of their proteins with other ligands. This mechanism is also important for signal transduction within cells. Protein phosphorylation on serine, threonine and tyrosine residues is done by enzymes known as protein kinases. It consists of almost 538 members which are divided into serine/threonine, histidine kinases and tyrosine.

Global dual specificity protein kinase TTK Inhibitors Market, is anticipated to be valued at US$ 51.92 Million over the forecast period.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2373

Impact of COVID-19:

The healthcare industry is still focusing on the developing therapies and vaccines for COVID-19. The pandemic has impacted clinical trials in many areas like dermatology, cardiovascular, and oncology.

Regulatory agencies like European Medicines Agency and the U.S. FDA have issued strict measures and guidelines for ensuring the safety, well-being of patients and integrity of trials during the outbreak. It has been very difficult to maintain track of clinical trials during the pandemic.

Carrying out clinical trials in the pandemic has many consequences like safety of patients, unavailability of staff and reallocation. Many supply chains were disrupted owing to the lockdowns and travel bans which also affected transporting samples to the central laboratories. Moreover, the pandemic led to extension of trial duration and delay in enrolling patients owing to this the study was either interrupted or slowed down. Furthermore, due to the lockdowns patients could not visit hospitals and it was difficult to conduct these trials. There was a need to limit the risk and also support participation of patients in clinical trials. Flexibility, innovation and appropriate use of pre-existing technologies were very important for adapting to the new paradigm.

Rising incidences of non-hematologic cancer is estimated to augment growth of the global dual specificity protein kinase TTK inhibitors market during the forecast period. The American Cancer Society provided statistics in 2021, stating that in the U.S., almost 235,760 new lung cancer cases were reported and it led to almost 131,880 fatalities.

Drivers:

Growing number of acquisitions by major players is anticipated to augment growth of the global dual specificity protein kinase TTK inhibitors market during the forecast period. For instance, Servier Laboratories declared the acquisition of Symphogen A/S June 2020. It is a subsidiary of Servier and it works as the antibody Center of Excellence of Servier in immune-oncology, primarily oncology and several therapeutic areas.

Key Takeaways:

The global dual specificity protein kinase TTK inhibitors market is estimated to witness a CAGR of 29.4% over the forecast period, owing to the rising increasing agreements amongst major players in the market. For instance, Boston Pharmaceuticals and Daiichi Sankyo Company, Limited declared a worldwide licensing agreement in August 2017, for novel RET inhibitor DS- 5010 by Daiichi Sankyo. This is a potent and highly selective RET kinase inhibitor.

The breast cancer segment, on the basis of application in the global dual specificity protein kinase TTK inhibitors market is estimated to witness significant growth over the forecast period. Rising research are being conducted on using TTK inhibitors for treating breast cancer, which is estimated to augment growth of the segment during the forecast period. For instance, an article was published in September 2018, in the Oncogenesis journal, mentioned the signaling pathways and role of TTK in regulating epithelial-to-mesenchymal transition (EMT) of triple negative (TN) breast cancer cells through TGF-β and KLF5 signaling. It also highlighted the signaling pathways of TTk inhibitors in breast cancer, representing TTK as a therapeutic target for treating breast cancer.

North America, among regions in the global dual specificity protein kinase TTK inhibitors market is estimated to witness robust growth over the forecast period, due to growing incidences of cancer in eth region. The National Cancer Institute published an article in 2021, stating that in the U.S. almost 1.9 million individuals will be diagnosed with cancer. It also mentioned that around 281,550 women and almost 2,650 men will be diagnosed with breast cancer.

Key players:

Key players active in the global dual specificity protein kinase TTK inhibitors market are Servier Laboratories, Bayer AG, Nerviano Medical Sciences S.R.L, Pfizer Inc. and Boston Pharmaceuticals.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2373

Reasons to buy this Dual Specificity Protein Kinase TTK Market Report

☑ It attempts an analysis of the competing scenario.

☑ The current and exceptional product revenue market.

☑ An in-depth data on the regional investigation and competitive landscape structure.

☑ It benefits in creating an awareness of the important key product segments.

☑ The marketing strategies, opportunities, and development factors are explained.

☑ Dual Specificity Protein Kinase TTK market size estimation and recent advancements in the industry are explained.

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Dual Specificity Protein Kinase TTK Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Dual Specificity Protein Kinase TTK Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Dual Specificity Protein Kinase TTK Industry Impact

Chapter 2 Global Dual Specificity Protein Kinase TTK Competition by Types, Applications, and Top Regions and Countries
2.1 Global Dual Specificity Protein Kinase TTK (Volume and Value) by Type
2.3 Global Dual Specificity Protein Kinase TTK (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Dual Specificity Protein Kinase TTK Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Dual Specificity Protein Kinase TTK Market Analysis
Chapter 6 East Asia Dual Specificity Protein Kinase TTK Market Analysis
Chapter 7 Europe Dual Specificity Protein Kinase TTK Market Analysis
Chapter 8 South Asia Dual Specificity Protein Kinase TTK Market Analysis
Chapter 9 Southeast Asia Dual Specificity Protein Kinase TTK Market Analysis
Chapter 10 Middle East Dual Specificity Protein Kinase TTK Market Analysis
Chapter 11 Africa Dual Specificity Protein Kinase TTK Market Analysis
Chapter 12 Oceania Dual Specificity Protein Kinase TTK Market Analysis
Chapter 13 South America Dual Specificity Protein Kinase TTK Market Analysis
Chapter 14 Company Profiles and Key Figures in Dual Specificity Protein Kinase TTK Business
Chapter 15 Global Dual Specificity Protein Kinase TTK Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology